Categories: News

Bio-Techne Begins Shipping Leo – A Next Generation High-Throughput Simple Western System

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MINNEAPOLIS, March 10, 2025 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.

Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance. 

“With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators and instruments,” commented Will Geist, President of Bio-Techne’s Protein Sciences Segment. “Leo will enable our customers to accelerate their cutting-edge science and bring next generation therapies to market faster.”

Early adopters have been thrilled with the power that Leo brings, with beta testers praising the instrument’s robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays, recombinant protein expression and more.

Explore Leo’s capabilities at bio-techne.com/leo. Data on Leo’s performance will be presented at an upcoming webinar. Registration details can be found here.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com 
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-begins-shipping-leo—a-next-generation-high-throughput-simple-western-system-302395190.html

SOURCE Bio-Techne Corporation

Staff

Recent Posts

Apollo Biowellness, Inc., Corporate Update

North Bergen, New Jersey--(Newsfile Corp. - August 18, 2025) - Apollo Biowellness, Inc. (OTC Pink:…

26 minutes ago

Red Light Holland Receives Initial Third-Party Psilocybin Testing Results via FDA-Compliant, DEA-Registered Partner, Irvine Labs

Initial testing results confirm psilocybin potency and process validation for potential medical grade manufacturing applicationsIrvine…

1 hour ago

Elucent Medical Launches SmartSupport™ – A Smarter Standard in Surgical Support 

MINNEAPOLIS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Elucent Medical is proud to announce the launch…

1 hour ago

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by…

1 hour ago